New Concepts in ADT
Dr. Thomas E. Keane presented "New Concepts in ADT" at the 27th annual International Prostate Cancer Update meeting on Thursday, January 26, 2017.
▶︎
What they don't tell you about Androgen Deprivation Therapy (ADT, hormone therapy)
▶︎
Active Surveillance Who is the Right Patient and What is the Right Protocol
▶︎
Active Surveillance: Past, Present, and Future
▶︎
Prostate Cancer Cure Explained: PSA, Recurrence, and Survival
▶︎
Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate Cancer
▶︎
High-risk prostate cancer: what patients and physicians should know in 2026
▶︎
Prostatakrebs: Neue Therapien, neue Perspektiven – Updates aus der Onkologie
▶︎
Genomic Testing for Prostate Cancer: Current Value in the Era of MRI and Clinical Prognostic Factors
▶︎
2025 PCRI #ProstateCancer Conference Q&A With Mark Scholz, MD & Mark Moyad, MD, MPH | #pcri
▶︎
Avoiding Decision Regret in Prostate Cancer Treatment
▶︎
Active Surveillance: Past, Present, Future with Dr. Todd Morgan
▶︎
PSA Rising? Ask These 3 Questions
▶︎
2025 Radiation & Side Effects For #ProstateCancer | Amar Kishan, MD & Q+A with Mark Moyad, MD #PCRI
▶︎
16 Years: Surviving Metastatic #ProstateCancer | Joel Nowak, CEO of @Cancer ABCs | #PCRI
▶︎
Overcoming Challenges to Treatment Adherence
▶︎
Prostate brachytherapy (seed implants) in 2026 explained for patients and physicians
▶︎
Biomarkers in secondary HLH/MAS: diagnosis, risk stratification, and disease monitoring
▶︎
Gleason 3+4 Prostate Cancer
▶︎
Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies
▶︎